7th Annual

Kinase Inhibitor Chemistry

Shaping Current and Future Development of Kinase Inhibitors

April 20-21, 2016

Kinase Inhibitor Chemistry icon  

Over the past decade, kinase drug discovery has resulted in the rapid and unparalleled development of a new generation of drugs, with over 25 small molecules currently approved by the FDA. As the rate of approval continues to accelerate, developers have found new ways to expand into a deeper portion of target space within the human kinome, moved beyond cancer and into chronic disease indications, particularly within CNS and cardiovascular disorders, as well as increased interest in allosteric modulation and covalently binding compounds. Although kinase drug discovery has already produced an impressive collection of approved therapies, this field remains one of the most vital and burgeoning arenas for pharmaceutical development. 

Cambridge Healthtech Institute’s 7th annual Kinase Inhibitor Chemistry will once again bring together academic and industry leaders to network, collaborate and discuss advances in kinase drug discovery.

Preliminary Agenda

Optimizing Next-Generation Kinase Inhibitors

An Integrated Approach to the Discovery, Development, and Clinical Use of Novel Kinase Inhibitors for the Treatment of Cancer

Shahrooz Rabizadeh, Ph.D., CSO, Research and Development, NantOmics, LLC; NantBioScience, Inc.

Focused Mapping for Characterizing Binding Sites and Setting up Ligand and Structure-Based Methods

Istvan Enyedy, Ph.D., Senior Scientist, Chemical and Molecular Therapeutics, Biogen

Mitochondrial Toxicity of all FDA Approved Tyrosine Kinase Inhibitors: Towards Safer New Drugs?

Qiang Shi, Ph.D., Visiting Scientist, Systems Biology, NCTR, FDA

Structural Basis for High Isoform Selectivity in a Class of Thiazolopiperidine Inhibitors of Phosphoinositide 3-Kinase γ

Philip Collier, Ph.D., Senior Research Scientist, Medicinal Chemistry, Vertex Pharmaceuticals Inc.

Covalent Inhibitor Development

Oxopyrido[2,3-d]Pyrimidines as Covalent L858R/T790M Mutant Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors

Ryan Wurz, Ph.D., Senior Scientist, Medicinal Chemistry, Amgen Inc.‬

Targeting JAK3 with Covalent Inhibitors

Chris Burns, Ph.D., Laboratory Head, Chemical Biology Division, Walter and Eliza Hall Institute, Australia

Design and Development of Novel Allosteric Modulators

CASE STUDY: Type II Kinase Inhibitors of IRE1 Allosterically Attenuate RNAse Activity to Reduce Apoptosis under Endoplasmic Reticulum Stress

Feroz Papa, M.D., Ph.D., Professor, Department of Medicine, Division of Endocrinology, University of California, San Francisco

Optimization of a Dibenzodiazepine Hit to a Potent and Selective Allosteric PAK1 Inhibitor

Andreas Marzinzik, Ph.D., Director, Lead Generation Chemistry, Novartis Institutes for BioMedical Research

Dynamics-Based Allostery in Protein Kinases

Alexandr P. Kornev, Ph.D., Project Scientist, Department of Pharmacology, University of California, San Diego

For more details on the conference, please contact:
Kip Harry
Conference Director
Cambridge Healthtech Institute
Phone: (+1) 781-972-5454
Email: kharry@healthtech.com

For partnering & sponsorship information, please contact:
Carolyn Benton
Business Development Manager
Cambridge Healthtech Institute
Phone: (+1) 781-972-5412
Email: cbenton@healthtech.com